You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Article info

Article menu

Download PDFPDF

Review
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Authors

  • Young Kwang Chae Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA Robert H. Lurie Comprehensive Cancer Center of Northwestern University 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA Northwestern University Feinberg School of Medicine 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA PubMed articlesGoogle scholar articles
  • Ayush Arya Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA PubMed articlesGoogle scholar articles
  • Wade Iams Northwestern University Feinberg School of Medicine 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA PubMed articlesGoogle scholar articles
  • Marcelo R. Cruz Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA PubMed articlesGoogle scholar articles
  • Sunandana Chandra Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA Robert H. Lurie Comprehensive Cancer Center of Northwestern University 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA Northwestern University Feinberg School of Medicine 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA PubMed articlesGoogle scholar articles
  • Jaehyuk Choi Robert H. Lurie Comprehensive Cancer Center of Northwestern University 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA Northwestern University Feinberg School of Medicine 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA PubMed articlesGoogle scholar articles
  • Francis Giles Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA Robert H. Lurie Comprehensive Cancer Center of Northwestern University 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA Northwestern University Feinberg School of Medicine 645 N. Michigan Avenue, Suite 1006 60611 Chicago IL USA PubMed articlesGoogle scholar articles
  1. ↵a 312 926 4248 young.chae{at}northwestern.edu
  2. ↵b ayush_7{at}msn.com
  3. ↵c Wade.iams{at}northwestern.edu
  4. ↵d marcelo.cruz{at}northwestern.edu
  5. ↵e sunandana.chandra{at}northwestern.edu
  6. ↵f jaehyuk.choi{at}northwestern.edu
  7. ↵g francis.giles{at}northwestern.edu
View Full Text

Citation

Chae YK, Arya A, Iams W, et al
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Journal for ImmunoTherapy of Cancer 2018;6:39. doi: 10.1186/s40425-018-0349-3

Publication history

  • Received October 1, 2017
  • Accepted May 2, 2018
  • First published May 16, 2018.
Online issue publication 
February 10, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.